BOTHELL, WA--(Marketwire - December 15, 2008) - MDRNA, Inc. (NASDAQ: MRNA) announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval of MDRNA’s Abbreviated New Drug Application (ANDA) for generic calcitonin-salmon nasal spray for the treatment of osteoporosis. Full FDA approval would follow the completion of Apotex’s 180-day exclusivity period, or June 2009.
